MX2020013240A - Sistema de administracion transnasal de la vacuna contra la hepatitis b. - Google Patents

Sistema de administracion transnasal de la vacuna contra la hepatitis b.

Info

Publication number
MX2020013240A
MX2020013240A MX2020013240A MX2020013240A MX2020013240A MX 2020013240 A MX2020013240 A MX 2020013240A MX 2020013240 A MX2020013240 A MX 2020013240A MX 2020013240 A MX2020013240 A MX 2020013240A MX 2020013240 A MX2020013240 A MX 2020013240A
Authority
MX
Mexico
Prior art keywords
hepatitis
vaccine
administration system
transnasal administration
vaccine composition
Prior art date
Application number
MX2020013240A
Other languages
English (en)
Inventor
Rubido Julio Cesar Aguilar
Arias Eduardo Penton
Taizou Kamishita
Takashi Miyazaki
Yoichi Hiasa
Osamu Yoshida
Mohammad Fazle Akbar Sheikh
Nieto Gerardo Enrique Guillen
Original Assignee
Toko Yakuhin Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toko Yakuhin Kogyo Kk filed Critical Toko Yakuhin Kogyo Kk
Publication of MX2020013240A publication Critical patent/MX2020013240A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B1/00—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means
    • B05B1/34—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl
    • B05B1/3405—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
    • B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
    • B05B11/02—Membranes or pistons acting on the contents inside the container, e.g. follower pistons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

La presente invención se refiere a un sistema de rinovacunación para prevenir y tratar la hepatitis B, que comprende una composición de vacuna contra la hepatitis B para administración a la mucosa nasal en combinación con un dispositivo de boquilla médico.
MX2020013240A 2018-06-05 2019-06-04 Sistema de administracion transnasal de la vacuna contra la hepatitis b. MX2020013240A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018107797 2018-06-05
PCT/JP2019/022136 WO2019235466A1 (ja) 2018-06-05 2019-06-04 Ｂ型肝炎ワクチン経鼻投与システム

Publications (1)

Publication Number Publication Date
MX2020013240A true MX2020013240A (es) 2021-05-12

Family

ID=68769323

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013240A MX2020013240A (es) 2018-06-05 2019-06-04 Sistema de administracion transnasal de la vacuna contra la hepatitis b.

Country Status (15)

Country Link
US (1) US20210187101A1 (es)
EP (1) EP3804752A4 (es)
JP (1) JPWO2019235466A1 (es)
KR (1) KR20210022009A (es)
CN (1) CN112368018A (es)
AU (1) AU2019283122A1 (es)
BR (1) BR112020022784A2 (es)
CA (1) CA3099430A1 (es)
CU (1) CU24686B1 (es)
IL (1) IL278415B2 (es)
MX (1) MX2020013240A (es)
PH (1) PH12020552075A1 (es)
SG (1) SG11202011004RA (es)
TW (1) TW202002950A (es)
WO (1) WO2019235466A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19851282A1 (de) * 1998-11-06 2000-05-11 Schweiz Serum & Impfinst Zusammensetzung einer pharmazeutisch wirksamen Substanz, appliziert in einem spezifischen Delivery-System zur Prävention und Behandlung von Infektions-Krankheiten
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
WO2002080648A2 (en) * 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
US20090306341A1 (en) 2005-07-29 2009-12-10 Joachim Emmert LC/MS Blends Containing Ionizing Additives
TW201414506A (zh) * 2006-04-21 2014-04-16 Toko Yakuhin Kogyo Kk 噴灑用凝膠型皮膚及／或黏膜附著型製劑及使用該製劑之投藥系統
WO2010114169A1 (en) 2009-03-31 2010-10-07 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
EP2832452B1 (en) 2012-03-30 2017-02-01 Yoshino Kogyosho Co., Ltd. Metered-dose syringe type spray device
JP6322844B2 (ja) * 2014-06-25 2018-05-16 東興薬品工業株式会社 医療用シリンジに用いられる点鼻用噴霧ノズル
KR102491446B1 (ko) * 2014-06-25 2023-01-20 도코 야쿠힌 고교 가부시키가이샤 인플루엔자 백신의 경비접종 시스템
JP6558392B2 (ja) * 2017-04-04 2019-08-14 ニプロ株式会社 シリンジ型噴出装置

Also Published As

Publication number Publication date
CA3099430A1 (en) 2019-12-12
SG11202011004RA (en) 2020-12-30
JPWO2019235466A1 (ja) 2021-06-24
CU20200097A7 (es) 2021-07-02
IL278415B2 (en) 2023-10-01
IL278415B1 (en) 2023-06-01
US20210187101A1 (en) 2021-06-24
EP3804752A1 (en) 2021-04-14
EP3804752A4 (en) 2022-03-09
AU2019283122A1 (en) 2020-11-26
PH12020552075A1 (en) 2021-05-31
CU24686B1 (es) 2023-11-07
KR20210022009A (ko) 2021-03-02
CN112368018A (zh) 2021-02-12
TW202002950A (zh) 2020-01-16
IL278415A (es) 2020-12-31
BR112020022784A2 (pt) 2021-02-02
WO2019235466A1 (ja) 2019-12-12

Similar Documents

Publication Publication Date Title
ZA202103404B (en) Composition and method for treating the lungs
SG10201807070YA (en) Respiratory mask with nasogastric tube path
PH12020551709A1 (en) Antiviral immunotropic agent for the treatment of acute respiratory viral infections
PH12020500555A1 (en) Esketamine for the treatment of depression
AR117632A1 (es) UN MÉTODO PARA ADMINISTRAR ÓXIDO NÍTRICO INHALADO (iNO)
MX2015012536A (es) Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc.
MX2021008247A (es) Combinacion de dextrometorfano y bupropion para el tratamiento de depresion.
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
MD20150120A2 (ro) Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei
AR098146A1 (es) Método y sistema mejorados para administrar por atomización un agente tensioactivo pulmonar
MX2018000258A (es) Dispositivo de suministro de un solo uso.
MX2017008000A (es) Sistema de inyeccion de un solo uso.
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
PH12015502274A1 (en) Lozenge for treating a sore throat, hoarseness, and associated dry cough and for treating inflammatory diseases of the oral cavity and of the pharynx
MY193963A (en) Composition for treating joint diseases and kit containing same
PH12020552075A1 (en) Hepatitis b vaccine transnasal administration system
MX2017013235A (es) Dispositivo para facilitar la administracion de un medicamento al pulmon mediante un catéter.
MX2018013475A (es) Acido carboxilico para tratar/prevenir congestion nasal.
MX2018011293A (es) Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma.
MX2021008329A (es) Farmaco profilactico o terapeutico para enfermedades neurodegenerativas.
MX2018011607A (es) Sultiame para el tratamiento de apnea del sueño.
MX2022007908A (es) Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
MX2019004736A (es) Mini-tabletas de melatonina y metodos de fabricacion de las mismas.
MX2015000696A (es) Sujetador de tubo endotraqueal para pacientes pediatricos.
TN2015000480A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias